The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $10.45

Today's change-0.03 -0.29%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $10.45

Today's change-0.03 -0.29%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Momenta Pharmaceuticals Inc down (U.S.)$0.03

Momenta Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$0.03 or 0.29% to (U.S.)$10.45. Over the last five days, shares have lost 11.21% and are down 29.58% for the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $10.62
  • Previous close(U.S.) $10.48
  • High(U.S.) $10.62
  • Low(U.S.) $9.91
  • Bid / Ask(U.S.) $0.00 / (U.S.) $18.70
  • YTD % change-29.58%
  • Volume935,115
  • Average volume (10-day)589,011
  • Average volume (1-month)791,264
  • Average volume (3-month)755,626
  • 52-week range(U.S.) $9.91 to (U.S.) $25.56
  • Beta1.89
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.19
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-79.30%

Although this company's net profit margin is negative, it is above the industry average and implies that Momenta Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue1445921
Total other revenue--------
Total revenue1445921
Gross profit--------
Total cost of revenue--------
Total operating expense44473137
Selling / general / administrative1213811
Research & development32342326
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-30-2-22-16
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-30-2-22-16
Income after tax-30-2-22-16
Income tax, total--------
Net income-30-2-22-16
Total adjustments to net income--------
Net income before extra. items-30-2-22-16
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-30-2-22-16
Inc. avail. to common incl. extra. items-30-2-22-16
Diluted net income-30-2-22-16
Dilution adjustment------0
Diluted weighted average shares68625452
Diluted EPS excluding extraordinary itemsvalue per share-0.44-0.04-0.40-0.31
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.44-0.04-0.40-0.31